A Phase III, Randomized, Double-blind, Multi-center Study to Compare the Immunological Efficacy and Safety of GC3102C With GC FLU Inj. Administered Intramuscularly in Healthy Adults
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GC 3102C (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 01 Jul 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 New trial record